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[~ Mannan-binding-lectin-associated serine protease 2 (MASP-2) - a 
major modifier of CF lung disease? 
H.V Olesen 1, J.C. Jensenius 2, R. Steffensen 3, S. Thiel 2, PO. Schiotz 1. 1Dept 
Pediatrics, Aarhus University Hospital, 2Dept Medical Microbiology and 
Immunology, University of Aarhus; 3 Dept Clinical Immunology, Aalborg Hospital, 
Denmark 
Aims: Activation of complement through the lectin pathway, part of the innate 
immune-defence against bacteria, is initiated by either mannan-binding-lectin 
(MBL) or the ficolins (H, M or L-ficolin) which are all in complex with a 
common protease, MBL-associated serine protease-2 (MASP-2). Some studies have 
associated deficiency of MBL with poorer outcome in CF lung disease. We explored 
the modifying effects of dysfunction of the lectin pathway by analysis of the 
MASP-2 dysfunction mutation (D105G) as well as MBL-2 genotypes. 
Methods: We analysed concentrations and genotypes of MASP-2 and MBL in 109 
CF patients (76 children and 33 adults), and correlated the results to lung function 
(FEV-1, FVC and FEF25 75) and chronic bacterial infections. 
Results: Patients heterozygous for the D105G mutation of MASP-2 had low 
concentrations of MASP-2, but normal MBL pathway function. We found no 
correlation to poor lung function. We found, however, one child homozygous for 
the mutation and with no pathway function. She had extremely severe lung disease 
with no other obvious precipitating factors. We found no correlation between MBL 
deficiency and poor lung function. Actually lung function was higher in patients 
with the genotypes resulting in deficiency/dysfunction of MBL (XA/YO+YO/YO) 
than with the other genotypes (p < 0.04). 
Conclusion: We describe the first CF patient homozygous for the D105G mutation 
of MASP-2, with otherwise unexplained severe lung disease. We suspect MASP-2 
dysfunction to be a major modifier of CF lung disease. Earlier reports of poorer 
outcome for MBL deficient patients were not supported by our findings. 
5. Immunology pulmonology 
l~  Surfactant protein D in BAL of children with CF 
J. Brazova 1 , A.P Pohunek 2, A. Sediva 1. 1Institute of Immunology, 2pediatric 
Clinic, University Hospital Motol, Prague, Czech Republic 
Introduction: Surfactant protein D (SP-D) is a member of pulmonary collectins 
that plays an important role in the first line lung defense mechanisms, enhances 
opsonization of microbes and limits lung inflammatory esponses. Our hypothesis 
was that insufficient production of SP-D in lungs of CF patients measured in bron- 
choalveolar lavage fluids (BAL) plays role in defect defense respiratory mechanisms 
in these patients. 
Patients and Methods: BAL from 15 CF children (mean 8.5 years, S.D. 3.9, 
10 female, 5 male) and 42 control subjects (mean 9.5 years, S.D. 6.3, 26 female, 
16 male) without CF (with respiratory diseases like bronchial asthma, bronchop- 
neumonia nd non respiratory diseases especially leukemias) undergoing clinically 
indicated bronchoscopy were investigated. Levels of SP-D (pg/ml) were measured 
in BAL supernatants u ing commercial available ELISA kit. Results were further 
interpreted in the context of acute state blood investigation. 
Results: In our pilot study with 15 CF children and 42 non CF controls production 
of SP-D was lower in CF (mean 335, S.D. 317) than in controls (mean 750, S.D. 
374) being statistically significant (p < 0.0015). In CF patients lung inflammation 
regarded to neutrophil counts was inversely correlated with SP-D levels. Neither 
age nor gender did affect SP-D levels. 
Conclusion: Insufficient production of SP-D in lungs in CF patients resolved in 
defect defense mechanisms. Therefore supplementation f SP-D might be a useful 
therapeutical target in CF patients to prevent infectious and inflammatory lung 
damage in these patients. 
Supported by: IGA MZ CR NR 8458 5, NR 7974 3, 006420301, IGA MSMT 
0021620812 and GACR 310/03/H147. 
[•] Mast cell activation and oxidative stress may be key factors in 
pulmonary destruction in Cystic Fibrosis 
PO. Schiotz 1, M. Kruhoffer 2, P Ebbesen 3, V Zachar 3, H.B. Andersen 1 ,
M. Holm 1 , H.V Olesen 1. 1ped. Dep. A, Aarhus University HosT., 2Dep. of Clin. 
Chem., Aarhus University HosT.; 3Lab. of Stem Cell Research, Aalborg Universily, 
Denmark 
Aims: To investigate the prostaglandin secretion from mast cells and its dependence 
on gluthtation concentration a d oxygen tension. 
Methods: Mast cells from controls and CF patients were cultured from peripheral 
blood CD133+ stem cells. Mast cells were incubated with IgE for 24 hours and then 
stimulated with anti-IgE. Before stimulation increasing concentrations of reduced 
glutathion were added to the cultures. After 30 rain. of stimulation prostaglandin 
was measured in the supernatant. Furthermore mastcells were cultured at 2%, 5% 
and 21% oxygen tension. 
Results: Increasing concentration f reduced glutathion was able to reduce prosta- 
glandin production with up to 50% in mast cells from CF patients as well as normal 
controls. 
Furthermore mast cell culture at 2% and 5% also inhibited prostaglandin synthesis 
with more than 50% compared to culture at 21% oxygen. This was prostaglandin 
specific since histamin release and receptor expression was unchanged in cultures 
at 5 and 21% oxygen. 
Conclusions: We hypothesize that prostaglandin synthesis depends on the amount 
of free oxygen radicals. This could explain why glutathion (a free radical scavenger) 
and reduced oxygen tension both reduce prostaglandin synthesis. Since concentra- 
tion of gluthation is reduced in epithelial lining fluid, this is in accordance with the 
clinical findings of increased mucus production and increased frequency of astmatic 
symptoms found in CF, both known prostaglandin effects. It further fits the effect of 
COX inhibitors (Ibuprofen), and the findings of abnormal prostaglandin metabolism 
previously published in CE 
~Pseudomonas aeruginosa flagellin is the major antigen for 
anti-pseudomonas IgY 
E. Nilsson 1 , H. Kollberg 2, M. Johannesson 2, B. Wretlind 3, A. Larsson 1. 1Dep. of 
Medical Sciences, University Hospital, 2 CF Cente~ University Childrens Hospital, 
Uppsala; 3 Dep. of Clinical Bacteriology, Div. of Laboratory Medicine, Karolinska 
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Aims: Pseudomonas eruginosa (PA) account for high morbidity and mortality in 
cystic fibrosis (CF) patients. CF patients with a chronic PA infection have more 
rapid deterioration of lung functions and the bacteria re impossible to eradicate 
from the lungs. Antibiotic resistant PA strains are steadily increasing. We have 
previously shown that specific chicken IgY antibodies against PA, anti-pseudomonas 
IgY (anti-PA IgY), purified from the egg yolk of hens immunized with PA may be 
an alternative to prevent PA infections in CF (Pediatr Pulmonol 2003; 35: 433). 
The number of positive PA cultures and the need of antibiotics have decreased 
significantly while lung function is maintained. Anti-PA IgY reduces PA adhesion 
to epithelia, but the mechanism has not been fully elucidated. 
Methods and Results: The immunoreactivity of anti-PA IgY was investigated 
to get further insight in the prophylactic effect of these antibodies. Flagellin was 
identified as the major antigen by 2D electrophoresis of PA strains, western blot 
and MALDI-TOF mass spectrometry. 
Discussion: Flagellin is the main protein of the flagella, involved in chemotaxis, 
motility, adhesion and inflammation and crucial for establishing infections in hosts. 
Furthermore, flagellin is secreted by PA, which elicits an inflammatory response. 
Earlier studies have both shown that flagellin mutants are much less infectious than 
flagellated strains and that antibodies against flagellin reduce PA infection. 
Conclusion: Anti-PA IgY binds flagellin, which may prevent PA infections in 
CF patients by reduced inflammation and less ability of host invasion. 
